WallStSmart
ORMP

Oramed Pharmaceuticals Inc

NASDAQ: ORMP · HEALTHCARE · BIOTECHNOLOGY

$4.62
+4.38% today

Updated 2026-06-04

Market cap
$149.38M
P/E ratio
1.39
P/S ratio
86.55x
EPS (TTM)
$2.62
Dividend yield
52W range
$2 – $5
Volume
0.2M

Oramed Pharmaceuticals Inc (ORMP) Financial statements

SEC filings — annual and quarterly data.

Profit margin
3,202.50%
Operating margin
-754.40%
ROE
58.20%
ROA
-4.28%
Debt/equity
0.00x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$-414576.00
2007$-3.24M
2008$-2.77M
2009$-2.76M
2010$-2.98M
2011$197412.00$-1.56M100.00%-1,233.60%-790.86%
2012$184254.00$-3.34M100.00%1,565.24%-1,815.15%
2013$-4.23M
2014$-5.70M
2015$-7.23M
2016$641000.00$-10.96M23.56%-1,561.62%-1,710.45%
2017$2.46M$-10.48M92.39%-438.56%-426.71%
2018$2.45M$-12.73M96.49%-552.35%-519.68%
2019$2.70M$-14.36M96.67%-541.29%-531.08%
2020$2.71M$-11.51M96.68%-433.84%-424.76%
2021$2.70M$-22.24M100.00%-896.15%-822.72%
2022$2.70M$-37.76M100.00%-1,501.96%-1,397.11%
2023$1.34M$5.53M100.00%-1,176.79%412.31%
2024$0.00$-19.10M
2025$2.00M$64.05M0.65%-754.40%3,202.50%

Frequently asked questions

How profitable is ORMP?

In its most recent fiscal year, ORMP ran a gross margin of 0.65%, an operating margin of -754.40%, and a net margin of 3,202.50%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ORMP generate?

ORMP produced $-11.08M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ORMP's balance sheet healthy?

ORMP holds $45.95M in cash and equivalents against — in long-term debt, on $199.74M of shareholder equity. That debt is best read against the cash flow the business throws off each year.